Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022
Ryo Kinoshita, Takeshi Arashiro, Noriko Kitamura, Satoru Arai, Koki Takahashi, Tadaki Suzuki, Motoi Suzuki, Daisuke Yoneoka
Abstract
A nationwide survey of SARS-CoV-2 antinucleocapsid seroprevalence among blood donors in Japan revealed that, as of November 2022, infection-induced seroprevalence of the population was 28.6% (95% CI 27.6%-29.6%). Seroprevalence studies might complement routine surveillance and ongoing monitoring efforts to provide a more complete real-time picture of COVID-19 burden.
Topics & Concepts
SeroprevalenceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineCoronavirus disease 2019 (COVID-19)VirologyPopulation2019-20 coronavirus outbreakImmunologySerologyEnvironmental healthAntibodyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies